Growup Pharma

B Pharmacy Sem 4: Pharmaceutical Organic Chemistry III

B Pharmacy Sem 4: Pharmaceutical Organic Chemistry III

Subject: Pharmaceutical Organic Chemistry III

1. Aromatic Electrophilic Substitution Reactions (Nitration, Sulfonation, Halogenation, Friedel–Crafts)
    2. Aromatic Nucleophilic Substitution Reactions
    3. Heterocyclic Chemistry (Five‐ and Six‐Membered Rings; Synthesis & Reactions of Pyrrole, Furan, Thiophene, Pyridine, Quinoline)
    4. Chemistry of Steroids and Antibiotics (Structural Features & Key Synthetic Steps)
    5. Pharmaceuticals: NSAIDs, Sulfa Drugs & Their Mechanisms
    6. Named Organic Reactions & Mechanisms (Wurtz, Sandmeyer, Reimer–Tiemann, etc.)

Table of Contents

 

Unit 1: Aromatic Electrophilic Substitution Reactions

This unit delves into the principles, mechanisms, and pharmaceutical relevance of electrophilic substitution on aromatic rings, covering nitration, sulfonation, halogenation, and Friedel–Crafts reactions.


1.1 Overview & General Mechanism

1.1.1 Definition

  • Reactions in which an electrophile (E⁺) replaces a hydrogen atom on an aromatic ring without disrupting aromaticity.

1.1.2 Mechanistic Steps

  1. Formation of Electrophile: Generation of a strong electrophile (e.g., NO₂⁺, SO₃H⁺, Cl⁺).

  2. σ‑Complex (Wheland Intermediate): Electrophile attacks the π‐system, forming a resonance‑stabilized arenium ion.

  3. Deprotonation & Aromaticity Restoration: A base removes H⁺ from the σ‑complex, regenerating the aromatic system.

1.1.3 Factors Affecting Reactivity & Orientation

  • Activating vs. Deactivating Groups:

    • Activators (–OH, –OCH₃) increase rate, direct ortho/para.

    • Deactivators (–NO₂, –C≡O) decrease rate, direct meta (unless strongly deactivating).

  • Steric Effects: Bulky substituents can hinder approach at ortho positions.


1.2 Nitration

1.2.1 Generation of Electrophile

  • Mixed acid: HNO₃ + H₂SO₄ → NO₂⁺ + HSO₄⁻ + H₂O.

1.2.2 Reaction Conditions & Regioselectivity

  • Temperature control (0–30 °C) to minimize poly‑nitration.

  • Activating groups favor ortho/para; deactivators favor meta.

1.2.3 Pharmaceutical Applications

  • Sulfa Drug Precursors: p‑Aminobenzoic acid nitration → p‑nitrobenzoic acid, reduced to p‑aminobenzoic acid.

  • Aryl Nitro Intermediates: Building blocks for aniline derivatives in antihistamines.


1.3 Sulfonation

1.3.1 Electrophile Formation

  • Fuming sulfuric acid (oleum): SO₃ + H₂SO₄ ↔ HSO₃⁺ + HSO₄⁻.

1.3.2 Equilibrium & Reversibility

  • High temperature drives desulfonation; low temperature (25–50 °C) favors sulfonation.

1.3.3 Uses in Drug Synthesis

  • Water‑Soluble Salts: Sulfonic acids (e.g., sulfonamide antibiotics) improve aqueous solubility.

  • Protecting Group Strategy: Temporary sulfonation to block positions during multi‑step syntheses.


1.4 Halogenation

1.4.1 Chlorination & Bromination

  • Catalyst: FeCl₃ or AlCl₃ for Cl₂; FeBr₃ for Br₂ → generates Cl⁺ or Br⁺.

  • Selectivity: Activators direct ortho/para; deactivators meta.

1.4.2 Iodination & Fluorination

  • Iodination: I₂ + oxidizer (HNO₃ or H₂O₂) → I⁺.

  • Fluorination: More challenging; often uses electrophilic reagents like Selectfluor.

1.4.3 Medicinal Chemistry Relevance

  • Halogenated Analogs: Modulate lipophilicity, metabolic stability, and receptor binding (e.g., chlorpromazine).

  • Radiolabeling: I‑131 or F‑18 incorporation for diagnostic imaging.


1.5 Friedel–Crafts Reactions

1.5.1 Alkylation

  • Electrophile: RCl + AlCl₃ → R⁺.

  • Limitations: Rearrangement of carbocations; polyalkylation; deactivated rings unreactive.

1.5.2 Acylation

  • Electrophile: RCOCl + AlCl₃ → RCO⁺.

  • Advantages: Deactivating acyl group prevents poly‑substitution; can be reduced later to alkyl.

1.5.3 Pharmaceutical Examples

  • Ketone Intermediates: Acylation to introduce benzoyl motifs in analgesics.

  • Spiro and Bicyclic Scaffolds: Friedel–Crafts cyclizations in steroid and alkaloid synthesis.


1.6 Key Mechanistic Insights & Named Reactions

1.6.1 Arenium Ion Stability

  • Resonance forms; substituent effects critical for transition‐state stabilization.

1.6.2 Common Pitfalls

  • Over‑reaction (polysubstitution), catalyst poisoning (deactivator groups), carbocation rearrangements.

1.6.3 Named Transformations

  • Gattermann–Koch Formylation (CO + HCl, AlCl₃/CuCl): Introduce –CHO on benzene.

  • Vilsmeier–Haack Reaction (DMF + POCl₃): Formylation of activated aromatics.


1.7 Key Points for Exams

  1. Draw Mechanisms: Full curved‐arrow mechanism for nitration and Friedel–Crafts acylation.

  2. Predict Products & Orientation: Given substituents, identify major isomer(s).

  3. Pharma Applications: Cite two examples where each type of reaction is used in drug synthesis.

  4. Compare Reactions: Advantages of Friedel–Crafts acylation vs. alkylation.

  5. Troubleshooting: Explain why polyalkylation occurs and strategies to avoid it.

 

Unit 2: Aromatic Nucleophilic Substitution Reactions

This unit examines how nucleophiles replace leaving groups on aromatic rings, focusing on the two main mechanisms—addition–elimination and benzyne pathways—and their relevance in pharmaceutical synthesis.


2.1 Overview & General Concepts

2.1.1 Definition

  • Replacement of an aromatic “leaving group” (commonly –NO₂, –Cl, –F) by a nucleophile (Nu⁻) under conditions that preserve or restore aromaticity.

2.1.2 Two Principal Mechanisms

  1. Addition–Elimination (SₙAr): Requires strong electron‑withdrawing groups ortho/para to the leaving group to stabilize the σ‑complex.

  2. Benzyne Mechanism: Occurs under harsh conditions when no activating groups are present; involves elimination to form a highly reactive benzyne intermediate.


2.2 Addition–Elimination (SₙAr)

2.2.1 Mechanistic Steps

  1. Nucleophilic Attack: Nu⁻ attacks the carbon bearing the leaving group, forming a non‑aromatic σ‑complex (Meisenheimer complex).

  2. Elimination: Departure of the leaving group (e.g., Cl⁻, F⁻) restores aromaticity.

2.2.2 Structural Requirements

  • Activating Groups: Strong electron‑withdrawing substituents (–NO₂, –CN, –SO₂R) at ortho/para positions increase reactivity.

  • Leaving Groups: Fluoride is often most reactive in SₙAr due to its strong inductive stabilization of the intermediate.

2.2.3 Reaction Conditions

  • Polar aprotic solvents (DMF, DMSO) to stabilize the nucleophile.

  • Elevated temperatures (80–150 °C) or phase‑transfer catalysis for sluggish systems.

2.2.4 Pharmaceutical Applications

  • Sulfonamide Synthesis: Nucleophilic displacement of chlorobenzenes to yield aryl sulfonamides (e.g., sulfamethoxazole).

  • Radiolabeling: ^18F–fluoride incorporation into aromatic rings for PET tracers via SₙAr on nitroarenes.


2.3 Benzyne Mechanism

2.3.1 Formation of Benzyne

  • Strong base (NaNH₂, t‑BuOK) induces elimination of HX (often H and a leaving group) to generate a triple‑bonded benzene intermediate.

2.3.2 Nucleophilic Capture

  • Nu⁻ adds to one of the benzyne carbons; protonation completes substitution, yielding a mixture of regioisomers.

2.3.3 Conditions & Limitations

  • Requires very strong bases and high temperatures (>200 °C).

  • Poor regioselectivity—often yields ortho and meta substituted isomers.

2.3.4 Drug Industry Examples

  • Aniline Synthesis: Historical route to aniline derivatives via benzyne from chlorobenzene; largely supplanted by milder methods.

  • Polymer Precursors: Manufacturing of specialty monomers where traditional SₙAr fails.


2.4 Practical Considerations & Variations

2.4.1 Leaving‑Group Effects

  • Order of reactivity: F > Cl > Br > I for SₙAr (opposite to electrophilic halogenations).

2.4.2 Nucleophile Types

  • Common nucleophiles: alkoxides (–OR), amines (–NH₂), thiolates (–SR), cyanide (–CN).

2.4.3 Catalytic & Phase‑Transfer Methods

  • Use of crown ethers or quaternary ammonium salts to transport inorganic nucleophiles into organic phase.


2.5 Key Points for Exams

  1. Mechanism Diagrams: Draw curved‑arrow mechanisms for both addition–elimination and benzyne pathways.

  2. Predict Reactivity: Given a substituted aryl halide, rank its susceptibility to SₙAr.

  3. Regioselectivity Rationale: Explain how ortho/para nitro groups direct and stabilize the Meisenheimer complex.

  4. Pharma Examples: Cite one SₙAr route to an important sulfonamide and one ^18F‑labeling procedure.

  5. Compare Mechanisms: List pros and cons of addition–elimination vs. benzyne in drug synthesis.

 

Unit 3: Heterocyclic Chemistry

A comprehensive exploration of five‐ and six‐membered heterocycles—focusing on their structures, methods of synthesis, characteristic reactions, and roles in pharmaceutical compounds.


3.1 Introduction to Heterocyclic Chemistry

3.1.1 Definition & Importance

  • Heterocycles are ring systems containing one or more heteroatoms (N, O, S) alongside carbon.

  • Over 75% of small‐molecule drugs feature heterocyclic scaffolds—crucial for binding specificity, solubility, and metabolic stability.

3.1.2 Classification

  • By Ring Size:

    • Five‑membered: Pyrrole, Furan, Thiophene

    • Six‑membered: Pyridine, Quinoline (fused benzopyridine)

  • By Saturation: Aromatic vs. partially or fully saturated analogs (e.g., piperidine, tetrahydrofuran).

3.1.3 Aromaticity Criteria

  • Planarity, cyclic conjugation, and Huckel’s rule (4n + 2 π‑electrons) determine aromatic stability.


3.2 Pyrrole

3.2.1 Structure & Properties

  • Formula C₄H₅N; 6 π‑electron aromatic ring with the lone pair on N delocalized into the π‑system.

  • Relatively acidic N–H (pKa ≈ 17) and highly activated at the 2‑ and 5‑positions for electrophilic substitution.

3.2.2 Key Syntheses

  1. Paal–Knorr Synthesis

    • 1,4‑Diketone + ammonia or primary amine → pyrrole (acid‐catalyzed cyclization).

  2. Hantzsch Synthesis Variation

    • α‑Amino ketone + α,β‑unsaturated carbonyl → pyrrole under acidic conditions.

3.2.3 Reactions

  • Electrophilic Substitution:

    • Nitration, halogenation occur at C‑2/C‑5 under mild conditions.

  • Metalation:

    • Lithiation at C‑2 allows for further cross‑coupling or alkylation.

  • Oxidation:

    • Over‐oxidation yields maleimide derivatives; controlled oxidation leads to functionalized pyrroles.

3.2.4 Pharmaceutical Relevance

  • Prostaglandins: Contain a 5‑membered ring related to pyrrole.

  • Anticancer Agents: E.g., select kinase inhibitors use substituted pyrrole cores.


3.3 Furan

3.3.1 Structure & Properties

  • Formula C₄H₄O; oxygen’s lone pair partly participates in aromatic sextet.

  • More reactive than benzene toward electrophiles; instability under strong acid or heat.

3.3.2 Syntheses

  1. Paal–Knorr Furan Synthesis

    • 1,4‑Diketone cyclodehydration under acid or base.

  2. Feist–Benary Reaction

    • α‑Halocarbonyl + β‑dicarbonyl + amine catalysis yields substituted furans.

3.3.3 Reactions

  • Diels–Alder Donor:

    • Acts as a diene in cycloadditions to build complex ring systems.

  • Electrophilic Substitution:

    • Occurs at C‑2, yielding 2‑substituted furans (e.g., formylation, halogenation).

  • Ring Opening:

    • Acidic or catalytic hydrogenation can open the ring to 1,4‑dicarbonyls.

3.3.4 Pharmaceutical Uses

  • Antimicrobials: Nitrofurans (e.g., nitrofurantoin) rely on furan’s redox chemistry.

  • Cardiovascular Drugs: Some calcium‐channel blockers incorporate furan units.


3.4 Thiophene

3.4.1 Structure & Properties

  • Formula C₄H₄S; sulfur contributes two electrons to aromatic sextet, conferring high stability.

  • Electron‐rich yet less reactive than furan; resistant to strong acids.

3.4.2 Synthetic Routes

  1. Paal–Knorr Thiophene Synthesis

    • 1,4‑Diketone + P₄S₁₀ (thionation) → thiophene.

  2. Gewald Reaction

    • α‑Cyano ketone + elemental sulfur + base → 2‑aminothiophenes.

3.4.3 Characteristic Reactions

  • Electrophilic Substitution:

    • Predominantly at C‑2; nitration, sulfonation, and halogenation under controlled conditions.

  • Metal‑Catalyzed Coupling:

    • Suzuki, Stille, or Negishi cross‑coupling at halogenated thiophenes to build conjugated systems.

3.4.4 Drug Applications

  • Antipsychotics & Antidepressants: E.g., many carry substituted thiophene rings for CNS activity.

  • Anti‑inflammatories: Some COX‑2 inhibitors include thiophene moieties.


3.5 Pyridine

3.5.1 Structure & Properties

  • Formula C₅H₅N; six‑membered aromatic ring where N’s lone pair resides in an sp² orbital (not part of π‑system)—accounts for basicity (pKa of conjugate acid ≈ 5.2).

  • Deactivated toward electrophiles, activated toward nucleophiles at ortho/para positions.

3.5.2 Synthesis Methods

  1. Hantzsch Dihydropyridine Synthesis

    • Aldehyde + two β‑ketoesters + ammonia → dihydropyridine → oxidized to pyridine.

  2. Bönnemann Cyclization

    • 1,5‑Diketones + ammonia/trityl salts under heat.

3.5.3 Reaction Chemistry

  • Electrophilic Substitution:

    • Requires strong Lewis acids; often leads to N‑oxide intermediates for further functionalization.

  • Nucleophilic Substitution:

    • 2‑ and 4‑positions can undergo SₙAr when converted to N‑oxide or with strong leaving groups.

  • Quaternization:

    • Formation of pyridinium salts—used as phase‑transfer catalysts or medicinal scaffolds.

3.5.4 Pharmaceutical Significance

  • Antituberculars: Isoniazid analogs feature hydrazide‐pyridine cores.

  • Cardiovascular Agents: Nicotinic acid (niacin) is a pyridine‐3‐carboxylic acid.


3.6 Quinoline

3.6.1 Structure & Properties

  • Fused benzene–pyridine system (C₉H₇N); aromatic in both rings with resonance across the bicyclic structure.

  • Basicity similar to pyridine; electrophilic and nucleophilic reactivity localized to the pyridine ring.

3.6.2 Synthetic Strategies

  1. Skraup Synthesis

    • Aniline + glycerol + H₂SO₄ + oxidant (nitrobenzene) → quinoline.

  2. Friedländer Synthesis

    • 2‑Aminoaryl ketone + carbonyl compound with α‑methylene → quinoline under acidic/basic catalysis.

3.6.3 Reactions & Functionalization

  • Electrophilic Substitution:

    • Occurs primarily on the benzene ring; directed by pyridine nitrogen’s -I effect.

  • Nucleophilic Addition at C‑2:

    • Grignard or organolithium reagents attack C‑2 of N‑oxide derivatives.

3.6.4 Role in Drug Design

  • Antimalarials: Quinine and chloroquine belong to quinoline family.

  • Antibacterials & Antineoplastics: Many exhibit intercalating or enzyme‑inhibitory activity through planar quinoline cores.


3.7 Comparative Summary & Applications

HeterocycleAromaticityKey ReactivityPharma Examples
Pyrrole6 π e–Electrophilic (C‑2)Prostaglandins, kinase inhibitors
Furan6 π e–Diels–Alder, C‑2 EASNitrofurans, calcium‑channel blockers
Thiophene6 π e–C‑2 EAS, couplingAntipsychotics, COX‑2 inhibitors
Pyridine6 π e–Nucleophilic (C‑2/4)Isoniazid, niacin
Quinoline10 π e–Benzene EAS, N‑oxideQuinine, chloroquine, anticancer intercalators

3.8 Key Points for Exams

  1. Mechanism Sketches: Show Paal–Knorr pyrrole synthesis, Skraup quinoline formation, and a Diels–Alder with furan.

  2. Reactivity Trends: Rank five heterocycles by ease of electrophilic substitution.

  3. Synthetic Design: Propose a route to 2‑aminothiophene using the Gewald reaction.

  4. Pharmaceutical Context: Match five heterocycles to their corresponding drug example and discuss why that ring was chosen.

  5. Aromaticity Rationalization: Explain why pyrrole’s lone pair contributes to aromaticity, whereas pyridine’s does not.

 

Unit 4: Chemistry of Steroids and Antibiotics

An in‑depth study of the structures, biosynthetic origins, key synthetic transformations, and pharmaceutical implications of steroids and major antibiotic classes.


4.1 Steroid Chemistry

4.1.1 Structural Framework

  • Cyclopentanoperhydrophenanthrene nucleus: Four fused rings (A, B, C six‑membered; D five‑membered) with 17 carbon atoms in core skeleton.

  • Numbering & Stereochemistry: Rigid trans‑junctions at A/B and B/C rings; methyl groups at C‑10 and C‑13, side chain at C‑17.

4.1.2 Biosynthesis & Natural Sources

  • Mevalonate Pathway: Acetyl‑CoA → isopentenyl pyrophosphate → squalene → lanosterol → cholesterol.

  • Plant Steroids: Diosgenin from yam; basis for semi‑synthetic corticosteroids and oral contraceptives.

4.1.3 Functional Group Variations

  • Hydroxylation Patterns: Positions C‑3, C‑11, C‑17 (e.g., cortisol has C‑11 OH).

  • Unsaturation: Δ⁵ (cholestene), Δ⁴ (pregnenolone); double bonds alter receptor affinity.

  • Side‑Chain Modifications: Pregnane (C₂₁), androstane (C₁₉), estrane (C₁₈) skeletons—defines progestogens, androgens, estrogens.

4.1.4 Key Synthetic Transformations

  1. Functionalization of Cholesterol

    • Oxidation at C‑3 → 3‑keto steroids; intermediate for corticosteroid synthesis.

    • Selective Δ¹⁴‑oxidation for glucocorticoid potency enhancement.

  2. Side‑Chain Cleavage

    • Hydrolysis & Oxidation to yield pregnane derivatives (e.g., progesterone).

  3. Introduction of Halogens

    • C‑9 Fluorination via electrophilic fluorinating agents to produce fludrocortisone.

  4. Ring Annulations & Rearrangements

    • Wagner–Meerwein shifts in ring contraction/expansion for bile acid analogs.

4.1.5 Pharmaceutical Steroids

  • Corticosteroids: Hydrocortisone (anti‑inflammatory), dexamethasone (enhanced potency via Δ¹⁴ and 9α‑fluoro).

  • Sex Hormones:

    • Progestins: Norethindrone (C‑17 ethynyl), medroxyprogesterone acetate.

    • Estrogens: Ethinylestradiol (C‑17α‑ethynyl for oral activity).

    • Androgens: Testosterone esters (propionate, enanthate for depot formulations).

4.1.6 Analytical & Quality Control

  • Spectroscopy: ¹H/¹³C NMR for ring junction stereochemistry; IR for carbonyl (1700 cm⁻¹).

  • Chromatography: HPLC methods with UV detection for potency and purity.

  • Solid‐State Assays: Polymorph screening (XRD) critical for bioavailability.


4.2 Antibiotic Chemistry

4.2.1 Classification & Core Scaffolds

  1. β‑Lactams: Penicillins, cephalosporins, carbapenems, monobactams (4‑membered lactam ring essential).

  2. Macrolides: 14‑ to 16‑membered lactone rings (e.g., erythromycin, azithromycin).

  3. Aminoglycosides: Aminocyclitol core with glycosidic sugars (e.g., gentamicin, streptomycin).

  4. Tetracyclines: Four fused rings (naphthacene nucleus).

  5. Others: Glycopeptides (vancomycin), oxazolidinones (linezolid), quinolones (fluoroquinolones).


4.2.2 β‑Lactam Antibiotics

4.2.2.1 Core Structure & Mode of Action

  • β‑Lactam Ring: Strained four‑membered amide; acylates transpeptidase enzyme active site, inhibiting cell‑wall crosslinking.

4.2.2.2 Biosynthesis & Semi‑Synthesis

  • Natural Precursors: 6‑APA (6‑aminopenicillanic acid) from Penicillium fermentation.

  • Side‑Chain Diversification: Acylation of 6‑APA → ampicillin, amoxicillin, methicillin (introduce steric hindrance for β‑lactamase resistance).

4.2.2.3 Key Synthetic Steps

  1. Fermentation for core penicillin nucleus.

  2. Chemical Acylation with activated acid chlorides or mixed anhydrides.

  3. Cephalosporin Expansion: Ring expansion from penam to cephem via ring‐opening and reclosure.

4.2.2.4 Resistance & Medicinal Chemistry

  • β‑Lactamases: Hydrolyze β‑lactam ring; overcome by bulky side chains or β‑lactamase inhibitors (clavulanic acid).

  • Medicinal Optimizations: Carbapenems (imipenem) resist most β‑lactamases due to trans configuration of C‑5 and C‑6 substituents.


4.2.3 Macrolide Antibiotics

4.2.3.1 Architecture & Biosynthesis

  • Lactone Core: 14‑membered ring assembled via polyketide synthases; sugars (desosamine, cladinose) attached glycosidically.

4.2.3.2 Semi‑Synthetic Modifications

  • Erythromycin → Clarithromycin: C‑6 O‑methylation to block acid‑catalyzed ketalization.

  • Azithromycin: Ring expansion to 15‑membered azalide improves acid stability and tissue penetration.

4.2.3.3 Mechanism & Pharmacology

  • 50S Ribosomal Binding: Blocks peptidyl transferase, inhibiting protein synthesis.

  • Resistance: Methylation of 23S rRNA; overcome by ketolides (telithromycin) with C‑11/C‑12 carbamate.


4.2.4 Aminoglycoside & Tetracycline Classes

4.2.4.1 Aminoglycosides

  • Core: 2‑deoxystreptamine or streptidine ring; glycosidic amino sugars.

  • Mode: Bind 30S ribosomal subunit → misreading of mRNA.

  • Modifications: Semisynthetic variants (amikacin) add L‑hydroxyaminobutyryl for stability against aminoglycoside‑modifying enzymes.

4.2.4.2 Tetracyclines

  • Scaffold: Four‑ring naphthacene core with multiple hydroxyl and dimethylamino substituents.

  • Action: Block aminoacyl‑tRNA binding to 30S unit.

  • Derivatives: Doxycycline (extra hydroxyl removed for improved pharmacokinetics), tigecycline (glycylamido moiety on C‑9 broadens spectrum).


4.3 Analytical Methods & Quality Control for Antibiotics

  • Microbial Assays: Zone‑of‑inhibition tests for potency.

  • HPLC/LC‑MS: Quantify parent drug and degradation products.

  • Chiral Purity: Critical for aminoglycosides (multiple stereocenters) via chiral HPLC.


4.4 Key Points for Exams

  1. Draw the steroid nucleus, label rings and key stereocenters; show how cholesterol converts to cortisol.

  2. Outline semi‑synthetic penicillin preparation from 6‑APA, including resistance‑conferring side chains.

  3. Compare macrolide modifications that improve acid stability (Clarithromycin vs. Erythromycin).

  4. Propose a synthetic route to a 9‑fluorinated corticosteroid starting from hydrocortisone.

  5. List two mechanisms of antibiotic resistance for β‑lactams and aminoglycosides, and corresponding medicinal chemistry strategies.

Unit 5: Pharmaceuticals – NSAIDs, Sulfa Drugs & Their Mechanisms

An extensive examination of non‑steroidal anti‑inflammatory drugs (NSAIDs) and sulfonamide (sulfa) antibiotics, covering their chemical structures, mechanisms of action, pharmacokinetics, therapeutic uses, adverse effects, and medicinal chemistry considerations.


5.1 Non‑Steroidal Anti‑Inflammatory Drugs (NSAIDs)

5.1.1 Overview & Classification
  • Definition: Drugs that relieve pain, reduce inflammation, and lower fever by inhibiting cyclooxygenase enzymes (COX‑1 and COX‑2), thereby decreasing prostaglandin synthesis.

  • Major Classes:

    • Salicylates: e.g., aspirin (acetylsalicylic acid)

    • Propionic Acid Derivatives: e.g., ibuprofen, naproxen

    • Acetic Acid Derivatives: e.g., diclofenac, indomethacin

    • Oxicams: e.g., piroxicam, meloxicam

    • COX‑2 Selective Inhibitors (Coxibs): e.g., celecoxib, etoricoxib


5.1.2 Mechanism of Action

5.1.2.1 Cyclooxygenase (COX) Isoforms

  • COX‑1: Constitutive enzyme involved in homeostatic functions (gastric mucosal protection, platelet aggregation, renal blood flow).

  • COX‑2: Inducible enzyme upregulated during inflammation; also constitutively expressed in some tissues (kidney, vascular endothelium).

5.1.2.2 Inhibition Kinetics

  • Aspirin: Irreversible acetylation of Ser530 (COX‑1) and Ser516 (COX‑2) → permanent inactivation in platelets.

  • Reversible Inhibitors: Ibuprofen and most others bind non‑covalently; duration dependent on plasma half‑life.

  • COX‑2 Selectivity: Bulkier side‑chains exploit a secondary pocket in COX‑2’s active site for selective binding.


5.1.3 Structure–Activity Relationships (SAR)

5.1.3.1 Salicylates

  • Aspirin: 2‑acetoxybenzoic acid; acetyl group critical for irreversible COX acetylation.

  • Diflunisal: 4′‑fluoro substitution increases potency and half‑life.

5.1.3.2 Propionic Acids

  • Ibuprofen: α‑methyl group enhances stereoselective COX binding; S‑enantiomer more active.

  • Naproxen: Secondary carboxylate and naphthyl moiety increase lipophilicity and duration.

5.1.3.3 Acetic Acids

  • Diclofenac: Two ortho‑chloro substituents on phenyl rings improve potency but also GI toxicity.

  • Indomethacin: Indole acetic acid scaffold with bulky p‑chlorobenzoyl group for high affinity.

5.1.3.4 Oxicams & Coxibs

  • Piroxicam: Enolic OH chelates active‑site Arg120 in COX.

  • Celecoxib: Diaryl‑substituted pyrazole core; sulfonamide moiety binds COX‑2 selectivity pocket.


5.1.4 Pharmacokinetics & Metabolism

5.1.4.1 Absorption & Distribution

  • Rapid GI absorption; high plasma protein binding (>90%).

  • Volume of distribution influenced by lipophilicity (e.g., naproxen more lipophilic than aspirin).

5.1.4.2 Metabolism

  • Phase I: Hepatic oxidation by CYP2C9 (diclofenac, celecoxib) or esterases (aspirin → salicylate).

  • Phase II: Conjugation (glucuronidation, sulfation) → inactive metabolites excreted renally.

5.1.4.3 Elimination

  • Half‑lives vary widely: aspirin (~0.3 h), ibuprofen (~2 h), naproxen (~14 h), piroxicam (~50 h).

  • Renal excretion of free drug and conjugates; dose adjustment in renal impairment.


5.1.5 Therapeutic Uses & Adverse Effects

5.1.5.1 Indications

  • Analgesia (mild–moderate pain), antipyresis, anti‑inflammation (arthritis, dysmenorrhea), cardiovascular prophylaxis (low‑dose aspirin).

5.1.5.2 Adverse Effects

  • Gastrointestinal: Gastric ulceration, bleeding (due to COX‑1 inhibition and decreased prostaglandins).

  • Renal: Reduced renal perfusion, electrolyte imbalance (sodium retention, hyperkalemia).

  • Cardiovascular: Hypertension exacerbation; increased risk of MI/stroke with COX‑2 inhibitors.

  • Hypersensitivity: Asthma exacerbation (aspirin‑induced), skin reactions.

5.1.5.3 Mitigation Strategies

  • Co‑administration of proton‑pump inhibitors or misoprostol.

  • Use of lowest effective dose; selective COX‑2 inhibitors in high GI‑risk patients.


5.2 Sulfonamide (Sulfa) Drugs

5.2.1 Historical Perspective & Overview
  • First effective systemic antibacterial agents; prontosil (azo‑prodrug) → sulfanilamide active metabolite.

  • Backbone: para‑aminobenzenesulfonamide structure mimics para‑aminobenzoic acid (PABA).


5.2.2 Mechanism of Action

5.2.2.1 Competitive Inhibition of Dihydropteroate Synthase (DHPS)

  • PABA Analogue: Sulfonamides compete with PABA for DHPS, blocking folate synthesis in bacteria (humans obtain folate from diet).

  • Bacteriostatic Effect: Inhibition of dihydrofolic acid formation → decreased nucleotide synthesis → halted DNA replication.

5.2.2.2 Synergism with Trimethoprim

  • Combined therapy (co‑trimoxazole) sequentially blocks DHPS and dihydrofolate reductase → bactericidal synergy.


5.2.3 Chemical Variations & SAR

5.2.3.1 Classical Sulfonamides

  • Sulfanilamide: p‑NH₂–C₆H₄–SO₂–NH₂ core; minimal side‑chain toxicity.

  • Sulphadiazine: Heterocyclic substituent (pyrimidine) at NH enhances spectrum.

5.2.3.2 Long‑Acting & Topical Agents

  • Sulfadoxine: p‑Methoxy at para‑amino → long half‑life (100 h) for malaria prophylaxis.

  • Sulfacetamide: Water‑soluble derivative for ophthalmic infections.

  • Silver Sulfadiazine: Topical burn ointment; silver provides additional antimicrobial action.

5.2.3.3 Solubility & Potency Modifications

  • Para‑substitution (alkyl, aryl) tunes lipophilicity and pharmacokinetics.

  • N₁‑acetylation in vivo → crystalluria risk; adjust dose and hydration.


5.2.4 Pharmacokinetics & Metabolism

5.2.4.1 Absorption & Distribution

  • Well‑absorbed orally; wide tissue distribution including CNS (e.g., sulfisoxazole crosses BBB).

  • High plasma protein binding (~90%) – potential for displacement interactions.

5.2.4.2 Metabolism

  • Acetylation (NAT enzymes) in liver → N¹‑acetyl metabolites (inactive, less water‑soluble).

  • Glucuronidation of –OH or –NH groups.

5.2.4.3 Elimination

  • Excreted primarily by kidney; both parent drug and metabolites.

  • Prolonged half‑life in neonates and elderly due to reduced renal function; monitor dosing.


5.2.5 Therapeutic Uses & Toxicity

5.2.5.1 Indications

  • Urinary tract infections, respiratory infections, certain protozoal diseases (e.g., toxoplasmosis, malaria prophylaxis).

  • Combined with trimethoprim for Pneumocystis jirovecii pneumonia in HIV.

5.2.5.2 Adverse Reactions

  • Hypersensitivity: Rash, Stevens–Johnson syndrome, toxic epidermal necrolysis.

  • Hematologic: Hemolytic anemia in G6PD deficiency; agranulocytosis, aplastic anemia.

  • Crystalluria: N¹‑acetyl sulfonamide precipitation in renal tubules—hydrate patients.

  • Kernicterus: Displacement of bilirubin in neonates—contraindicated in late pregnancy and infants.


5.3 Key Medicinal Chemistry Strategies

  1. Prodrug Design: Prontosil’s azo linkage → activated in vivo to sulfanilamide; aspirin’s acetyl group → salicylic acid.

  2. Selectivity Tuning: COX‑2 selectivity via steric bulk; sulfonamide spectrum via heterocycle variation.

  3. Toxicity Mitigation: Minimizing reactive metabolites (e.g., diclofenac → quinone imines), optimizing solubility to prevent crystalluria.


5.4 Key Points for Exams

  1. Draw Mechanisms: Show aspirin’s acetylation of COX‑1 serine and sulfonamide competition with PABA at DHPS.

  2. Compare Classes: List three differences between propionic acid NSAIDs and acetic acid NSAIDs in terms of SAR and toxicity.

  3. Case Study: Explain why celecoxib has lower GI toxicity but higher cardiovascular risk.

  4. Design Problem: Propose a para‑substituent to enhance sulfonamide solubility and justify choice.

  5. Clinical Correlation: Describe co‑trimoxazole’s synergistic mechanism and clinical indications.

Unit 6: Named Organic Reactions & Mechanisms

This unit surveys classic named transformations—detailing mechanisms, conditions, scope, and pharmaceutical applications of key reactions such as Wurtz, Sandmeyer, Reimer–Tiemann, and others.


6.1 Wurtz Reaction

6.1.1 Reaction Overview

  • Definition: Coupling of two alkyl halides (R–X) in sodium metal/ether to form a higher alkane (R–R).

  • General Equation:

    2 R–X + 2 Na → R–R + 2 NaX

6.1.2 Mechanism

  1. Single‐Electron Transfer (SET): Na donates an electron to R–X → R· (radical) + NaX

  2. Radical Coupling: Two R· radicals recombine → R–R

  3. Side Pathways: R· + R–X → R–X + R· (chain); formation of mixed coupling products with two different halides.

6.1.3 Reaction Conditions & Limitations

  • Solvent: Dry diethyl ether to stabilize radicals and solvated sodium.

  • Substrate Scope: Best for primary halides; secondary/tertiary give poor yields due to rearrangements and elimination.

  • Major Drawback: Poor selectivity—statistical mixture if two different R–X used.

6.1.4 Pharmaceutical Relevance

  • Historical use in constructing symmetrical alkyl chains in lipid‐mimetic drug carriers.

  • Nowadays largely of pedagogical interest; replaced by more selective coupling (e.g., Grignard, Suzuki).


6.2 Sandmeyer Reaction

6.2.1 Reaction Overview

  • Definition: Replacement of an aryl diazonium salt with halide or pseudohalide via copper(I) catalysis.

  • General Transformations:

    • Ar–N₂⁺ Cl⁻ + CuCl → Ar–Cl

    • Ar–N₂⁺ Br⁻ + CuBr → Ar–Br

    • Ar–N₂⁺ + CuCN → Ar–CN

6.2.2 Mechanism

  1. Diazonium Formation: Ar–NH₂ + NaNO₂ + HCl → Ar–N₂⁺ Cl⁻

  2. Copper(I)–Mediated SET: Cu(I) reduces Ar–N₂⁺ → Ar· + N₂ + Cu(II)

  3. Radical Capture: Ar· + Cu(II)–X → Ar–X + Cu(I)

6.2.3 Conditions & Variations

  • Temperature: 0–5 °C for diazotization; reaction warmed for coupling.

  • Scope: Introduce Cl, Br, CN, SCN, OH (via Cu₂O/H₂O), etc.

  • Limitations: Sensitive to functional groups that react with radicals; competing phenol formation under aqueous conditions.

6.2.4 Pharmaceutical Applications

  • Synthesis of aryl nitriles (–CN) as precursors for heterocycles (e.g., pyridines) in drug scaffolds.

  • Preparation of halogenated aromatics for further cross‐coupling (e.g., Suzuki–Miyaura).


6.3 Reimer–Tiemann Reaction

6.3.1 Reaction Overview

  • Definition: Formylation of phenols at ortho positions using chloroform and base to yield salicylaldehydes.

  • General Equation:

    Ar–OH + CHCl₃ + 3 KOH → Ar–(2‑CHO) + 3 KCl + H₂O

6.3.2 Mechanism

  1. Carbene Generation: CHCl₃ + OH⁻ → :CCl₃ + Cl⁻ + H₂O

  2. Electrophilic Attack: :CCl₃ attacks ortho position of phenoxide → dichlorocarbene adduct.

  3. Hydrolysis & Dechlorination: Base‐mediated removal of Cl’s → formyl group.

6.3.3 Reaction Conditions & Regioselectivity

  • Base: Strong (KOH or NaOH), often in aqueous/alcoholic medium.

  • Temperature: Reflux for several hours.

  • Selectivity: Ortho favored by coordination of phenoxide; para product minor unless ortho blocked.

6.3.4 Pharmaceutical Uses

  • Preparation of salicylaldehyde derivatives—key intermediates for Schiff base drugs and flavoring agents.

  • Building block for coumarin synthesis via subsequent Perkin or Knoevenagel reactions.


6.4 Other Key Named Reactions

6.4.1 Friedländer Synthesis
  • Purpose: Construction of quinoline rings by condensation of 2‑aminobenzaldehyde with ketones bearing α‑methylene.

  • Mechanism: Schiff base → intramolecular aldol condensation → dehydration → quinoline.

6.4.2 Kolbe–Schmitt Reaction
  • Purpose: Carboxylation of phenolates to yield salicylic acids (e.g., aspirin precursor).

  • Mechanism: CO₂ under pressure (100–200 atm) at 125–150 °C attacks phenoxide at ortho → salicylate → acidification.

6.4.3 Gabriel Phthalimide Synthesis
  • Purpose: Preparation of primary amines: phthalimide + KOH → phthalimide anion + R–X → phthalimide‑N‑alkyl → hydrazinolysis → R–NH₂.

  • Mechanism: SN2 on phthalimide anion; followed by deprotection.

6.4.4 Clemmensen Reduction & Wolff–Kishner Reduction
  • Clemmensen: Acidic Zn/Hg reduction of ketones to alkanes.

  • Wolff–Kishner: Base‐promoted hydrazone → diimide → alkane.

  • Pharma Use: Selective removal of carbonyl functionalities in complex drug intermediates.

6.4.5 Michael Addition
  • Purpose: Conjugate addition of nucleophiles (enolates, thiols, amines) to α,β‑unsaturated carbonyls.

  • Mechanism: Nucleophile adds to β‑carbon → enolate → protonation.

  • Utility: C–C bond formation in steroid side‑chain elaboration and heterocycle synthesis.


6.5 Comparative Mechanistic Insights

ReactionKey IntermediateConditionsPharma Application
WurtzAlkyl Radical (R·)Na, etherLipid‐chain coupling (historical)
SandmeyerAryl Radical (Ar·)Cu(I), diazoniumAryl–CN and halide synthesis
Reimer–TiemannDichlorocarbene (:CCl₃)CHCl₃, KOH, refluxSalicylaldehyde intermediates
Kolbe–SchmittCarboxylate AnionCO₂ (high P, T)Salicylic acid (aspirin precursor)
Michael AdditionEnolateBase, polar solventsC–C bond formation in steroids, heterocycles

6.6 Key Points for Exams

  1. Mechanism Drawings: Show full curved‐arrow for Sandmeyer and Reimer–Tiemann.

  2. Condition Rationale: Explain why Reimer–Tiemann requires chloroform/strong base but Kolbe–Schmitt uses CO₂/pressure.

  3. Selectivity Discussion: Compare ortho vs. para carboxylation in Kolbe–Schmitt and Reimer–Tiemann.

  4. Pharma Examples: For each reaction, name one drug or intermediate synthesized via that route.

  5. Limitation Solutions: Propose modern alternatives (e.g., Pd‐catalyzed couplings vs. Wurtz).

 

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
Scroll to Top